	Application No.	Applicant(s)
Notice of Allowability	Application No.	Applicant(s)
	10/663,033	TAYLOR ET AL.
	Examiner	Art Unit
	Christian L. Fronda	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the AMENDMENT dated 12/21/2005.		
2. The allowed claim(s) is/are <u>55,56,58-60,62-64,66-68 and 70-82</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicla such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 Marie (1.6	A 14 11 11 (DTO 150)
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 		atent Application (PTO-152)
	6. ☐ Interview Summary Paper No./Mail Dat 8), 7. ☑ Examiner's Amendn	(PTO-413), e
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	8), 7. ⊠ Examiner's Amendn	nent/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. X Examiner's Stateme	nt of Reasons for Allowance
or biological material	9.	

Application/Control Number: 10/663,033 Page 2

Art Unit:

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jennifer L. Wahlsten on 03/01/2006.

- 2. The application has been amended as follows:
- In claim 55, line 9, after the phrase "(SEQ ID NO: 4)", insert the phrase "wherein the bioactive fragment has alpha-1,2-fucosyltransferase activity".
- In claim 59, line 8, after the phrase "(SEQ ID NO: 4)", insert the phrase "wherein the bioactive fragment has alpha-1,2-fucosyltransferase activity".
- In claim 63, line 8, after the phrase "(SEQ ID NO: 4)", insert the phrase "wherein the bioactive fragment has alpha-1,2-fucosyltransferase activity".
- In claim 67, line 8, after the phrase "(SEQ ID NO: 4)", insert the phrase "wherein the bioactive fragment has alpha-1,2-fucosyltransferase activity".
- In claim 71, line 1, after the phrase "wherein the", insert the phrase "alpha-1,2-fucosyltransferase"
- In claim 71, line 2, replace the phrase "SEQ ID NO: 2", with the phrase "SEQ ID NO: 1".

Allowable Subject Matter

- 3. Claims 55, 56, 58-60, 62-64, 66-68, and 70-82 are allowed.
- 4. The following is an examiner's statement of reasons for allowance: Following a diligent search it was determined that prior art neither teaches nor suggests the claimed method for producing an alpha-1,2-fucosylated oliogosaccharide blood type antigen using

Art Unit:

a *Helicobacter* alpha-1,2-fucosyltransferase polypeptide, wherein the alpha-1,2-fucosyltransferase polypeptide is encoded by a polynucleotide identical to a polynucleotide that is amplified by PCR using *Helicobacter* genomic DNA as template and primers of SEQ ID NO: 3 and SEQ ID NO: 4.

- 5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928.
- 7. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866 217 9197 (toll free).

CLF

PRIMARY EXAMINER